Contraindications and higher-risk situations: This should include higher-risk situations like pregnancy, prior severe reactions, and certain endocrine history
Olivier Rascol, a neurologist at Toulouse University Hospital, presents another hypothesis, with implications for neurodegenerative diseases: GLP-1 drugs could be reducing inflammation
The fact that GLP drugs target appetite regulation at the hormonal level makes them a promising tool for sustainable weight loss, particularly for those who have struggled with traditional diet and exercise approaches
Mendelian randomization (MR) employed GLP1R cis-eQTLs as instrumental variables to assess links with mood/behavior-related disorders
CrossRef The neuro-metabolic epidemic and the CB1R paradox Francesca Vaccaro, Ginevra Malta, Manfredi Rizzo, Fulvio Plescia, Gianluca Lavanco Current Opinion in Pharmacology.2026